Aisling Capital related stories
All articles and analysis
VC-backed Monte Rosa Therapeutics debuts IPOMonte Rosa Therapeutics Inc, a developer of small molecule precision medicines, has raised about $222.3 million for its IPO after pricing its 11.7 million shares at $19 per share.
- Elevation Oncology nets $32.5m Series A
New York City-based Elevation Oncology, a clinical-stage biopharmaceutical company, has raised $32.5 million in Series A financing.
Medical device firm Ajax Health rakes in more than $85 mlnAjax Health, a medical device firm, has raised more than $85 million in funding. HealthQuest Capital led the round with participation from Aisling Capital and Polaris Partners.
- BridgeBio Pharma racks up $299.2 mln
BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, has raised $299.2 million in funding. KKR and Viking Global Investors led the round with participation from other investors that included Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, Hercules Capital and Sequoia Capital.
- Biotech firm Atreca rakes in $125 mln Series C
Redwood City, California-based Atreca Inc, a biotechnology company, has secured $125 million in Series C financing. The investors included Wellington Management Company LLC, Cormorant Asset Management, Aisling Capital, Boxer Capital of the Tavistock Group, EcoR1 Capital, Redmile Group, Samsara BioCapital and funds managed by Tekla Capital Management.
